Human Germline Genome Editing

被引：139

作者：

Ormond, Kelly E. ^{[1
,2
]}

Mortlock, Douglas P. ^{[3
,4
]}

Scholes, Derek T. ^{[5
]}

Bombard, Yvonne ^{[6
]}

Brody, Lawrence C. ^{[7
]}

Faucett, W. Andrew ^{[8
,9
]}

Garrison, Nanibaa' A. ^{[10
,11
]}

Hercher, Laura ^{[9
,12
]}

Isasi, Rosario ^{[13
,14
]}

Middleton, Anna ^{[15
,16
]}

Musunuru, Kiran ^{[17
,18
]}

Shriner, Daniel ^{[19
,20
]}

Virani, Alice ^{[21
,22
,23
]}

Young, Caroline E. ^{[5
]}

机构：

[1] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA

[2] Stanford Univ, Sch Med, Stanford Ctr Biomed Eth, Stanford, CA 94305 USA

[3] Vanderbilt Univ, Vanderbilt Genet Inst, Nashville, TN 37232 USA

[4] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA

[5] Amer Soc Human Genet, Bethesda, MD 20814 USA

[6] Univ Toronto, St Michaels Hosp, Inst Hlth Policy Management & Evaluat, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada

[7] NHGRI, Div Genom & Soc, Bethesda, MD 20892 USA

[8] Geisinger Hlth Syst, Genom Med Inst, Danville, PA 17822 USA

[9] Natl Soc Genet Counselors, Chicago, IL USA

[10] Seattle Childrens Hosp & Res Inst, Treuman Katz Ctr Pediat Bioeth, Seattle, WA 98101 USA

[11] Univ Washington, Dept Pediat, Div Bioeth, Seattle, WA 98101 USA

[12] Sarah Lawrence Coll, Joan H Marks Grad Program Human Genet, Bronxville, NY 10708 USA

[13] Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn Dept Human Genet, Miami, FL 33136 USA

[14] Univ Miami, Miller Sch Med, Inst Bioeth & Hlth Policy, Miami, FL 33136 USA

[15] Connecting Sci, Soc & Eth Res Grp, Wellcome Genome Campus, Cambridge CB10 1SA, England

[16] Assoc Genet Nurses & Counsellors, London, England

[17] Univ Penn, Dept Med, Perelman Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA

[18] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA

[19] NHGRI, Ctr Res Genom & Global Hlth, Bethesda, MD 20892 USA

[20] Int Genet Epidemiol Soc, Bethesda, MD USA

[21] Univ British Columbia, Prov Hlth Serv Author British Columbia, Vancouver, BC V6H 3N1, Canada

[22] Univ British Columbia, Dept Med Genet, Vancouver, BC V6H 3N1, Canada

[23] Canadian Assoc Genet Counsellors, Oakville, ON, Canada

来源：

AMERICAN JOURNAL OF HUMAN GENETICS | 2017年 / 101卷 / 02期

关键词：

HEALTH TECHNOLOGY-ASSESSMENT; CAS9; NUCLEASES; HUMAN-CELLS; CRISPR-CAS9; SPECIFICITY; CHILDREN; ENDONUCLEASE; CRISPR/CAS9; INTEGRATION; GENERATION;

D O I：

10.1016/j.ajhg.2017.06.012

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

With CRISPR/Cas9 and other genome-editing technologies, successful somatic and germline genome editing are becoming feasible. To respond, an American Society of Human Genetics (ASHG) workgroup developed this position statement, which was approved by the ASHG Board in March 2017. The workgroup included representatives from the UK Association of Genetic Nurses and Counsellors, Canadian Association of Genetic Counsellors, International Genetic Epidemiology Society, and US National Society of Genetic Counselors. These groups, as well as the American Society for Reproductive Medicine, Asia Pacific Society of Human Genetics, British Society for Genetic Medicine, Human Genetics Society of Australasia, Professional Society of Genetic Counselors in Asia, and Southern African Society for Human Genetics, endorsed the final statement. The statement includes the following positions. (1) At this time, given the nature and number of unanswered scientific, ethical, and policy questions, it is inappropriate to perform germline gene editing that culminates in human pregnancy. (2) Currently, there is no reason to prohibit in vitro germline genome editing on human embryos and gametes, with appropriate oversight and consent from donors, to facilitate research on the possible future clinical applications of gene editing. There should be no prohibition on making public funds available to support this research. (3) Future clinical application of human germline genome editing should not proceed unless, at a minimum, there is (a) a compelling medical rationale, (b) an evidence base that supports its clinical use, (c) an ethical justification, and (d) a transparent public process to solicit and incorporate stakeholder input.

引用

页码：167 / 176

页数：10

共 50 条

[1] Human germline genome editing
Rebecca A. Lea
Kathy K. Niakan
[J]. Nature Cell Biology, 2019, 21 : 1479 - 1489
[2] Human germline genome editing
Lea, Rebecca A.
Niakan, Kathy K.
[J]. NATURE CELL BIOLOGY, 2019, 21 (12) : 1479 - 1489
[3] Human Germline Genome Editing: An Assessment
Greely, Henry T.
[J]. CRISPR JOURNAL, 2019, 2 (05): : 253 - 265
[4] Vulnerability and the Ethics of Human Germline Genome Editing
Labude, Markus K.
Xafis, Vicki
Lai, Poh San
Mills, Catherine
[J]. CRISPR JOURNAL, 2022, 5 (03): : 358 - 363
[5] Democratic Governance of Human Germline Genome Editing
Jasanoff, Sheila
Hurlbut, J. Benjamin
Saha, Krishanu
[J]. CRISPR JOURNAL, 2019, 2 (05): : 266 - 271
[6] Author Correction: Human germline genome editing
Rebecca A. Lea
Kathy K. Niakan
[J]. Nature Cell Biology, 2020, 22 (1) : 135 - 135
[7] Human germline genome editing: The public and the pundits
Baylis, F.
[J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1063 - 1063
[8] Human germline genome editing and broad societal consensus
Françoise Baylis
[J]. Nature Human Behaviour, 1
[9] Human germline genome editing: the ASHG position statement
Ormond, K.
[J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 766 - 767
[10] Human germline genome editing and broad societal consensus
Baylis, Francoise
[J]. NATURE HUMAN BEHAVIOUR, 2017, 1 (06):

← 1 2 3 4 5 →